Literature DB >> 10077333

Intrathecal substance P-induced thermal hyperalgesia and spinal release of prostaglandin E2 and amino acids.

X Y Hua1, P Chen, M Marsala, T L Yaksh.   

Abstract

Substance P is an important neuromediator in spinal synaptic transmission, particularly in processing nociceptive afferent information. The effects of substance P are mediated by activation of the neurokinin 1 receptor. Evidence has suggested that excitatory amino acids such as glutamate, and prostaglandins including prostaglandin E2 are involved in the enhanced spinal excitability and hyperalgesia produced by spinal substance P. In the present study, we have demonstrated that intrathecal injection of substance P (20 nmol) in rats chronically implanted with intrathecal dialysis catheters induced a decrease in thermal paw withdrawal latency (before: 10.4+/-0.3 s; after 7.6+/-0.6 s), which was accompanied by an increase in prostaglandin E2 (362+/-37% of baseline), glutamate (267+/-84%) and taurine (279+/-57%), but not glycine, glutamine, serine or asparagine. Intrathecal injection of artificial cerebrospinal fluid had no effect upon the behavior or release. Substance P-induced thermal hyperalgesia and prostaglandin E2 release were significantly attenuated by a selective neurokinin 1 receptor antagonist RP67580, but not by an enantiomer RP68651. However, substance P-induced release of glutamate and taurine was not reduced by treatment with RP67580. SR140333, another neurokinin 1 receptor antagonist, displayed the same effects as RP67580 (i.e. block of thermal hyperalgesia and prostaglandin E2 release, but not release of amino acids). These results provide direct evidence suggesting that the spinal substance P-induced thermal hyperalgesia is mediated by an increase in spinal prostaglandin E2 via activation of the neurokinin 1 receptor. These findings define an important linkage between small afferents, sensory neurotransmitter release and spinal prostanoids in the cascade of spinally-mediated hyperalgesia. The evoked release of glutamate is apparently not a result of activation of neurokinin 1 receptors. Accordingly, consistent with other pharmacological data, acute spinal glutamate release does not contribute to the hyperalgesia induced by activation of spinal neurokinin 1 receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10077333     DOI: 10.1016/s0306-4522(98)00488-6

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  20 in total

1.  Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists.

Authors:  K J Powell; W Ma; M Sutak; H Doods; R Quirion; K Jhamandas
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

Review 2.  The spinal biology in humans and animals of pain states generated by persistent small afferent input.

Authors:  T L Yaksh; X Y Hua; I Kalcheva; N Nozaki-Taguchi; M Marsala
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

3.  In vitro prostanoid release from spinal cord following peripheral inflammation: effects of substance P, NMDA and capsaicin.

Authors:  D M Dirig; T L Yaksh
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

4.  Substance P inhibits progesterone conversion to neuroactive metabolites in spinal sensory circuit: a potential component of nociception.

Authors:  Christine Patte-Mensah; Cherkaouia Kibaly; Ayikoe G Mensah-Nyagan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-10       Impact factor: 11.205

5.  Spinal prostaglandins are involved in the development but not the maintenance of inflammation-induced spinal hyperexcitability.

Authors:  E Vasquez; K J Bär; A Ebersberger; B Klein; H Vanegas; H G Schaible
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

6.  The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1.

Authors:  T L Yaksh; D M Dirig; C M Conway; C Svensson; Z D Luo; P C Isakson
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

7.  Spinal administration of lipoxygenase inhibitors suppresses behavioural and neurochemical manifestations of naloxone-precipitated opioid withdrawal.

Authors:  Tuan Trang; Maaja Sutak; Remi Quirion; Khem Jhamandas
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

8.  Contribution of neurokinin 1 receptors in the cutaneous orofacial inflammatory pain.

Authors:  Philippe Luccarini; Mélaine Henry; Pedro Alvarez; Anne-Marie Gaydier; Radhouane Dallel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-27       Impact factor: 3.000

9.  Effect of memantine on the levels of neuropeptides and microglial cells in the brain regions of rats with neuropathic pain.

Authors:  Katsumichi Takeda; Mai Muramatsu; Toshiyuki Chikuma; Takeshi Kato
Journal:  J Mol Neurosci       Date:  2009-08-04       Impact factor: 3.444

10.  Role of prostaglandins in spinal transmission of the exercise pressor reflex in decerebrated rats.

Authors:  A J Stone; S W Copp; M P Kaufman
Journal:  Neuroscience       Date:  2014-07-05       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.